Cargando…

Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory disorder that requires sustained treatment for optimal outcomes. The 5-aminosalicylate (5-ASA) class of medications are first-line for the treatment of mild-to-moderate UC but suffer from suboptimal adherence rates in real-world settings. This review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripathi, Kartikeya, Dong, Jeffrey, Mishkin, Brooke F, Feuerstein, Joseph D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412827/ https://www.ncbi.nlm.nih.gov/pubmed/34511961 http://dx.doi.org/10.2147/CEG.S237653

Ejemplares similares

New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance
por: Tripathi, Kartikeya, et al.
Publicado: (2019)

Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis
por: Lee, Jin, et al.
Publicado: (2019)

Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates
por: Freeman, Hugh James
Publicado: (2012)

Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
por: Mikami, Yohei, et al.
Publicado: (2023)

5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018)

The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
por: He, Long, et al.
Publicado: (2021)

Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis
por: Yan, Yan, et al.
Publicado: (2018)

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis
por: Yan, Yan, et al.
Publicado: (2019)

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
por: Park, Soo-Kyung, et al.
Publicado: (2022)

5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis
por: Xu, Jun, et al.
Publicado: (2018)

Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care
por: Jayasooriya, Nishani, et al.
Publicado: (2023)

5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis
por: Zhao, Li-Na, et al.
Publicado: (2014)

Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis
por: Uchiyama, Kazuhiko, et al.
Publicado: (2023)

Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation
por: dos Santos, Lana Claudinez, et al.
Publicado: (2015)

Therapeutic Efficacy of the Combination Therapy of Corticosteroids and 5-Aminosalicylic Acid for Treatment of Pyoderma Gangrenosum with Ulcerative Colitis
por: Chen, Wei, et al.
Publicado: (2020)

Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis
por: Olaisen, Maya, et al.
Publicado: (2019)

A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis
por: Liu, Baohai, et al.
Publicado: (2017)

Fecal microbiota transplantation treatment for refractory ulcerative colitis with allergy to 5-aminosalicylic acid: A case report
por: Wang, Hong-Gang, et al.
Publicado: (2018)

Adherence in ulcerative colitis: an overview
por: Testa, Anna, et al.
Publicado: (2017)

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
por: Mizuno, Shinta, et al.
Publicado: (2020)

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
por: Fukuda, Tomohiro, et al.
Publicado: (2020)

Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis
por: Li, Hui-biao, et al.
Publicado: (2018)

Ulcerative Colitis Impairs the Acylethanolamide-Based Anti-Inflammatory System Reversal by 5-Aminosalicylic Acid and Glucocorticoids
por: Suárez, Juan, et al.
Publicado: (2012)

Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials
por: Jiang, Yong, et al.
Publicado: (2016)

Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis
por: Chen, Yan, et al.
Publicado: (2022)

The impact of obesity on hospitalized patients with ulcerative colitis
por: El-Dallal, Mohammed, et al.
Publicado: (2021)

Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase
por: Madarame, Akira, et al.
Publicado: (2021)

Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2016)

Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis
por: Chen, Mu-yuan, et al.
Publicado: (2019)

A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn’s disease and ulcerative colitis
por: Jeličić, Mario-Livio, et al.
Publicado: (2020)

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial
por: Peng, Lijun, et al.
Publicado: (2019)

A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study
por: Kawakami, Aki, et al.
Publicado: (2014)

Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study
por: Fossmark, Reidar, et al.
Publicado: (2021)

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice
por: Ben-Horin, Shomron, et al.
Publicado: (2017)

Is there a standardized practice for the development of international ulcerative colitis and Crohn’s disease treatment guidelines?
por: Goldowsky, Alexander, et al.
Publicado: (2021)

Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
por: Bernick, Steven J, et al.
Publicado: (2010)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
por: Sood, Ajit, et al.
Publicado: (2020)

Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy
por: Schierová, Dagmar, et al.
Publicado: (2020)

The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry
por: Fukuda, Tomohiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cnnopp64puj3816qeur6a99f4o